

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 June 2020 (11.06.2020)



(10) International Publication Number
WO 2020/118213 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) A61K 31/138 (2006.01)
A61K 31/015 (2006.01) A61K 45/06 (2006.01)
A61K 31/137 (2006.01)

(21) International Application Number:

PCT/US2019/065005

(22) International Filing Date:

06 December 2019 (06.12.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/776,323 06 December 2018 (06.12.2018) US

(71) Applicant: **RADIUS PHARMACEUTICALS, INC.**
[US/US]; 950 Winter Street, Waltham, MA 02451 (US).

(72) Inventors: **PATEL, Hitisha**; 59 Las Casas Street, Malden, MA 02148 (US). **BIHANI, Teeru**; 950 Winter Street, Waltham, MA 02451 (US). **ARLT, Heike**; 10 Cheviot Road, Arlington, MA 02474 (US). **TAO, Nianjun**; 21 Brookings Street, Medford, MA 02155 (US).

(74) Agent: **DOYLE, Kathryn, D.**; Honigman LLP, 650 Trade Centre Way, Suite 200, Kalamazoo, MI 49002-0402 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: METHODS FOR TREATING CANCER RESISTANT TO CDK4/6 INHIBITORS




FIG. 1A

(57) Abstract: Disclosed herein are methods of treating a CDK4/6 inhibitor resistant estrogen receptor alpha-positive cancer in a subject having either a wild-type estrogen receptor alpha and/or a mutant estrogen receptor alpha, the method comprising administering to the subject a therapeutically effective amount of elacestrant, or a pharmaceutically acceptable salt or solvate thereof, wherein the mutant estrogen receptor alpha comprises one or more mutations selected from the group consisting of D538G, Y537X₁, L536X₂, P535H, V534E, S463P, V392I, E380Q and combinations thereof, wherein: X₁ is S, N, or C; and X₂ is R or Q. In some embodiments, the CDK4/6 inhibitor resistant estrogen receptor alpha-positive cancer is selected from the group consisting of breast cancer, uterine cancer, ovarian cancer, and pituitary cancer.



WO 2020/118213 A1